Den 8. august 2001 meddelte Bayer, at man frivilligt suspenderede markedsføringen og distributionen af cerivastatin i både EU og USA, mens man afventede yderligere evaluering af risikoen for rabdomyolyse i forbindelse med behandling med cerivastatin.
On 8 August 2001 Bayer announced that it was voluntarily suspending its marketing and distribution of cerivastatin from both the European and US markets pending further evaluation of the risk of rhabdomyolysis associated with its use.